Covidien Unlimited Co.

DUBLIN--( BUSINESS WIRE )--The "Raw Material Requirements (Health Canada/USP/EP) in a cGMP Environment - Issues and Solutions Training Course" training has been added to ResearchAndMarkets.com's offering. The World Compliance seminars team has come up with a detailed course on raw material compliance to understand the intricacy of an ingredient in a product. We have enforced the idea of good manufacturing practices through several pharmaceutical GMP training programs. However, minute elements like raw materials need critical attention to avoid warning letters. Every biotech product is an amalgam of multiple raw materials that add purpose and efficiency to it. Since raw materials are the foundation of these products, it is important to have regulatory norms in place for them. Hence, this seminar discusses raw material compliance to ensure every final product meets FDA expectations and guidelines. Course Overview Did you know more than 5000 firms received the notice for not having cGMP-controlled raw materials? This is not a scenario you dream of while running a pharmaceutical and biotech manufacturing business. As much as the cGMP course plays an essential role, concerned personnel needs to understand regulatory requirements for raw materials. The basic framework of this course is different from cGMP online training. It includes topics like testing and approval of the raw materials, rejection criteria of components, product container management, and closures. As far as the benefits of pharmaceutical cGMP training are concerned, you will learn the following things: Basic guidelines to formulate representative samples for effective testing and inspection Best practices to release each component, packaged product, and closures Appropriate techniques to collect samples alongside preventing contamination, maintaining sterility in equipment, and aseptic processing General criteria for testing and examination of the samples Impact of multiple raw materials on the end user Adhere to the best practices required for commercial-grade manufacturing In addition to these general topics, here are the topics that will be discussed in the seminar. Who Should Attend: Raw material compliance is currently the talk of the town and upskilling yourself will help you in building a positive career. Moreover, additional knowledge of cGMP violations will help you excel in the department. Below are some professionals who will benefit from this FDA compliance training: Regulatory and Compliance Professionals: Develop the ability to identify loopholes and build a better system for raw material procurement and processing. Manufacturing and Quality Engineers: Assess the quality of the product internally and set a benchmark for the entire team to avoid warning letters and product recalls. Document Control Specialists: Gain perspective on documenting the characteristics of the raw material appropriately for future reference. Quality Auditors : In-house auditors play an essential role in product examination and are responsible for giving critical feedback on the entire system. Project Managers: The course will help them understand basic regulations related to raw materials so they can take suitable action and manage product development. 12.0 RAC CREDITS RAPS - This course has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Speakers: Barry A. Friedman, Ph.D Consultant Cambrex Bio Sciences Dr. Friedman possesses over 30 years of industrial managerial experience in various aspects of biopharmaceuticals and medical devices to include regulatory compliance, expert witness testimony, GLP/GMP, quality control, auditing, sterility assurance, microbiological/analytical validations and fermentation technology. Prior to becoming an independent consultant, Dr. Friedman was associated with Cambrex Bio Sciences, a contract manufacturer of GMP bulk biopharmaceuticals located in Baltimore, Maryland. As the Director of Quality Control, he managed a multi-shift Department of thirty one individuals involved in client management, the receipt and testing of raw materials, environmental monitoring and microbiology, analytical chemistry and QC compliance for the production of Phase 1, 2, 3 and commercial products manufactured from bacteria, yeast and mammalian cells. In this capacity, Dr Friedman enjoyed many client and regulatory interactions, both domestic and international. Prior to 2000, Dr. Friedman was the Laboratory Director for Chesapeake Biological Laboratories, a contract Aseptic Fill n' Finish manufacturer located in Baltimore, Maryland. In addition to the professional history listed above, other associations have included W.R. Grace, Sigma Chemical Co., Sherwood Medical, Becton Dickinson, American Cyanamid and Union Carbide. Dr. Friedman received his B.S. degree in Microbiology from Ohio State University, his M.S. from Michigan State University in Microbial Genetics, and his PhD from Ohio State University in Microbiology. For more information about this training visit https://www.researchandmarkets.com/r/w04u4w About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Tigris Trial Enrollment Reaches 126 Patients Strengthened Balance Sheet with Expected Funds to Complete Tigris Trial Enrollment TORONTO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the second quarter ended June 30, 2024, and provided a corporate update. Spectral has continued its significant progress throughout the second quarter of 2024 both clinically and operationally and year-to-date enrolled 45 patients for a total of 126 patients out of the 150 total patients target. The Company is focused on the final push to fully enroll and finish the Tigris trial and believes that the continued onboarding of new Tigris sites since the fourth quarter of 2023 could further accelerate enrollment and allow Spectral to rapidly reach the 150-patients target, bringing the Company closer to FDA submission and potential FDA approval. In parallel to its clinical trial, the Company continues to work closely with its commercialization partner, Baxter. Dr. John Kellum, Chief Medical Officer of Spectral Medical, stated, “We continue to witness robust enrollment activity in 2024, with record enrollment rates since the beginning of the year. Tigris is gathering momentum as we enter the final months of the trial. We have a very strong group of sites and very dedicated investigators, and the excitement level has never been higher. Our clinical team is focused on trial site support with activities to ensure that our Tigris sites have the support and resources to enroll patients as efficiently as possible. We are committed alongside our trial sites to advancing Tigris and believe PMX, if ultimately approved, will play a major role in reducing the tragic rates of mortality caused by sepsis.” “I am pleased with the increased level of activity across the Company and the resultant ramp up of patient enrollment. The potential to sustain our current pace of enrollment could see us rapidly advance the trial towards completion in the late 2024 timeframe,” said Chris Seto, Chief Executive Officer of Spectral. “Additionally, with the receipt of gross proceeds of approximately $11 million since the beginning of April, we have secured funding to finalize Tigris enrollment.” Corporate Highlights During & Subsequent to Second Quarter 2024 Tigris Trial and Regulatory Program Patient EnrollmentTotal of 126 patients randomized to date out of the 150 total patients to be enrolled in the Tigris trial. Accelerated enrollment experienced in the second quarter and 2024 to date, with 45 patients enrolled so far – represents the most robust enrollment rates since the start of the Tigris trial.Record monthly enrollment with nine patients enrolled in June, followed equally with nine patients enrolled in July. Tigris SitesCurrently 23 Tigris sites onboarded, with the onboarding of the Thomas Jefferson University, which is an experienced, high-quality site from the EUPHRATES trial. Spectral clinical team focused on trial site management activities to ensure that Tigris sites have the support and resources to enroll patients as efficiently as possible. TimingThe Company continues to focus on finalizing the Tigris trial within the reasonably shortest timelines. Based on the current rate of enrollment, Tigris could be completed as early as December 2024. PMX Commercialization Baxter Partnership ActivitiesIn anticipation of a positive Tigris trial outcome, the Company has been working closely with Baxter on post-approval marketing plans for PMX commercialization. This includes developing product branding, pricing and roll-out plans with numerous Baxter departments, including marketing, regulatory, clinical and reimbursement. Baxter has communicated its intention to undertake a broad marketing campaign on day one of FDA approval for PMX. Prismax Sub-studyThe Company is also working with Baxter on a sub-study to obtain FDA clearance for hemoperfusion for Baxter’s Prismax device. The Prismax, with its leading installed base in ICUs throughout the U.S., is anticipated to be the primary ICU device utilized for PMX treatments on commercial launch. Funding Bought Deal Private Placement Convertible NotesOn May 30, 2024, Spectral received USD $6,232 in convertible notes payable (the “Notes”) upon the completion of its private placement. 6,232 Notes were issued and have a face value of USD$1,000 per Note, bearing interest of 9% and are due May 1, 2028 (the “maturity date”). Holders of the notes may convert all or any portion of the Notes into common shares of the Company in integral multiples of USD $1,000 principal amount at any time prior to the maturity date. The Notes are convertible into approximately 16,359,000 Common Shares representing a conversion price of approximately CAD$0.52 per share subject to certain anti-dilution and make whole fundamental change adjustments. Exercise of Anti-Dilution Pre-emptive Rights On July 19, 2024 the Company completed an additional non-brokered offering of US$1 million of 9% convertible notes of the Company (the “Notes”) at a price of US$1,000 per convertible note due on May 1, 2028 (the “Offering”). The Notes were sold to one of the Company’s largest shareholders pursuant to the exercise of their anti-dilution pre-emptive rights relating to the closing of the offering of the approximately CAD$8.5 million offering of Notes that was completed on May 30, 2024. Share Warrant Exercise / Expired WarrantsSubsequent to the second quarter end 207,500 share warrants were exercised for gross proceeds of approximately $102,250. These warrants were issued in conjunction with the Company’s July 27, 2021 and November 2, 2022 unit offerings.On July 29, 2024, 10,982,500 share warrants expired. These expired share warrants were issued in conjunction with the Company’s approximately $10 million unit offering which closed on July 27, 2021. As at the time of this MD&A, the Company has 7,775,464 share warrants outstanding. Stock Option Exercise1,799,460 stock options were exercised in the second quarter for gross proceeds of approximately $606,000. Almost all of the stock options exercised were held by the board and management of the Company, including Spectral’s CEO (Mr. Chris Seto), Board Chairman (Dr. Paul Walker), Director (Mr. William Stevens) and now former Director (Mr. Anthony Bihl). Addition to Spectral Board of Directors On June 7, 2024, the Company announced that it had appointed Mr. Cristiano Franzi to its Board of Directors. Mr. Franzi is a seasoned global healthcare executive and board director with a 30-year track record at leading global Med-Tech companies. As Regional President for businesses of up to $4 billion in size at Solventum, Baxter, Medtronic, and Covidien, Mr. Franzi has proven his ability to deliver value by developing compelling visions, identifying new market opportunities, and articulating clear growth strategies while streamlining operations and implementing highly disciplined business models. Change of Auditors On July 11, 2024, the Company announced that MNP has been appointed as the auditors of the Company following the decision by PricewaterhouseCoopers LLP (“PWC”) to resign as the auditor of Spectral. The PWC resignation was not the result of any disagreement between the Company and PWC on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure. Financial Review Revenue for the three-months ended June 30, 2024 was $471,000 compared to $306,000 for the same three-month period last year, representing an increase of $165,000 or 54%. Revenue for the six-months ended June 30, 2024, was $1,139,000 and $836,000 for the same period last year, representing an increase of $303,000 or 36%. Royalty revenue for the three-months ended June 30, 2024 was NIL and NIL for the same period the prior year. Royalty revenue for the six-months ended June 30, 2024 was $135,000 compared to $126,000 for the same six-month period last year. This is due to an increase in usage of the Company’s IP from one customer. Product Revenue for the three-months ended June 30, 2024 was $218,000 compared to $139,000 for the same three-month period last year, representing an increase of $79,000 or 56%. Product revenue for the six-months ended June 30, 2024 was $567,000 and $376,000, representing an increase of $191,000 or 51%. Operating expenses for the three-months ended June 30, 2024, were $4,873,000, compared to $4,594,000 for the same period in the prior year, an increase of $279,000, or 6%. Interest expense increased by $418,000 due to convertible notes payable issued on September 7, 2023 and May 30, 2024. Also, an increase in the raw material and consumables used, and foreign exchange loss. Operating expenses for the six-months ended June 30, 2023, were $9,698,000 compared to $6,219,000 for the same period in the prior year, an increase of $3,479,000 or 56%. The change is primarily due to an increase in foreign exchange loss of $781,000, interest expense increase of $711,000, fair value adjustment derivative liability increase of $455,000 and amortization expense increase of $516,000. All these increases are due to the funding received during September 2023 and May 2024. In addition, share-based compensation expense increased by $295,000. Lastly, consulting and professional fees increased by $270,000 due to increased site and patient fees related to the Tigris trial. Clinical development and regulatory program costs were $1,413,000 for the three-months ended June 30, 2024 compared to $1,563,000 for the same period in the prior year. For the six-months ended June 30, 2024, clinical development costs were $2,377,000 compared to $1,994,000 for the corresponding period the prior year. A significant portion of clinical trial and regulatory costs consists of consulting and professional fees paid to contract research organizations, clinical sites, and other clinical and regulatory consultants. The increase in costs reflects increased activity with respect to the initialization of clinical sites and the randomization of patients into the Tigris clinical trial. Loss for the three-months ended June 30, 2024 was $4,402,000, $(0.02) per share compared to a loss of $4,239,000, $(0.02) per share for the same period in the prior year. The increased loss of $163,000 was due to increased operating expenses, partially offset by a reduction in loss from discontinued operations of $49,000 related to the reduction in Dialco operating expenses. Loss for the six-months ended June 30, 2024 was $8,562,000, $(0.03) per share, compared to a loss of $5,377,000, $(0.02) per share, for the same period in the prior year. The increased loss of $3,185,000 was due to operating expenses, partially offset by a reduction in loss from discontinued operations of $3,000 related to the reduction in Dialco operating expenses. The Company concluded the second quarter of 2024 with cash of $7,536,000 compared to $2,952,000 of cash on hand as of December 31, 2023. The total number of common shares outstanding for the Company was 281,245,539 at June 30, 2024. About Spectral Spectral is a Phase 3 company seeking U.S. FDA approval for its unique product for the treatment of patients with septic shock, Toraymyxin™ (“PMX”). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s Endotoxin Activity Assay (EAA™), the only FDA cleared diagnostic for the risk of developing sepsis. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. In March 2009, Spectral obtained the exclusive development and commercial rights in the U.S. for PMX, and in November 2010, signed an exclusive distribution agreement for this product in Canada. In July 2022, the U.S. FDA granted Breakthrough Device Designation for PMX for the treatment of endotoxic septic shock. Approximately 330,000 patients are diagnosed with septic shock in North America each year. The Tigris Trial is a confirmatory study of PMX in addition to standard care vs standard care alone and is designed as a 2:1 randomized trial of 150 patients using Bayesian statistics. Endotoxic septic shock is a malignant form of sepsis https://www.youtube.com/watch?v=6RANrHHi9L8. The trial methods are detailed in “Bayesian methods: a potential path forward for sepsis trials”. Spectral is listed on the Toronto Stock Exchange under the symbol EDT. For more information, please visit www.spectraldx.com. Forward-looking statement Information in this news release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information, particularly in respect of the future outlook of Spectral and anticipated events or results, are assumptions based on beliefs of Spectral's senior management as well as information currently available to it. While these assumptions were considered reasonable by Spectral at the time of preparation, they may prove to be incorrect. Readers are cautioned that actual results are subject to a number of risks and uncertainties, including the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Spectral to take advantage of business opportunities in the biomedical industry, the granting of necessary approvals by regulatory authorities as well as general economic, market and business conditions, and could differ materially from what is currently expected. The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For further information, please contact: Ali Mahdavi Chris SetoCapital Markets & Investor Relations CEOSpinnaker Capital Markets Inc. Spectral Medical Inc.416-962-3300 am@spinnakercmi.com cseto@spectraldx.com Spectral Medical Inc.Condensed Interim Consolidated Statements of Financial PositionIn CAD (000s), except for share and per share data(Unaudited) June 30, December 31, Notes 2024 2023 $ $ Assets Current assets Cash 7,536 2,952 Trade and other receivables 352 186 Inventories 272 366 Prepayments and other assets 932 621 9,092 4,125 Non-current assets Right-of-use-asset 505 567 Property and equipment 294 326 Intangible asset 184 193 Total assets 10,075 5,211 Liabilities Current liabilities Trade and other payables 2,784 2,820 Current portion of contract liabilities6 525 727 Current portion of lease liability 125 121 Notes payable7 334 264 Derivative Liability7 11,266 6,310 15,034 10,242 Non-current liability Lease liability 436 500 Non-current portion of contract liabilities6 5,291 3,342 Notes payable7 12,157 7,676 Total liabilities 32,918 21,760 Shareholders' (deficiency) equity9 Share capital 88,501 87,061 Contributed surplus 8,916 8,916 Share-based compensation 11,091 10,385 Warrants 2,648 2,526 Deficit (133,999)(125,437)Total shareholders' (deficiency) equity (22,843)(16,549)Total liabilities and shareholders' (deficiency) equity 10,075 5,211 Spectral Medical Inc.Condensed Interim Consolidated Statements of Loss and Comprehensive LossIn CAD (000s), except for share and per share data(Unaudited) Revised Revised (Refer Note 15) (Refer Note 15) Notes Three months ended June 30, 2024 Three months ended June 30, 2023 Six-months ended June 30, 2024 Six-months ended June 30, 2023 $ $ $ Revenue6 471 306 1,139 836 Expenses Raw materials and consumables used 388 281 667 418 Salaries and benefits13 1,023 976 2,023 1,932 Consulting and professional fees 1,445 1,472 2,370 2,100 Regulatory and investor relations 126 196 301 304 Travel and entertainment 195 99 271 183 Facilities and communication 143 81 263 164 Insurance 105 100 210 187 Depreciation and amortization 549 103 680 164 Interest expense7 668 250 1,208 497 Foreign exchange loss 65 (201)529 (252)Share-based compensation9 1,079 987 1,256 961 Other expense - (51)(12)(79)Net loss on joint arrangement5 - 78 - 163 Fair value adjustment derivative liabilities7 (913)223 (68)(523) 4,873 4,594 9,698 6,219 Loss and comprehensive loss for the period from continuing operations (4,402)(4,288)(8,559)(5,383)Loss (gain) from discontinued operations5 - 49 (3)6 Loss and comprehensive loss for the period (4,402)(4,239)(8,562)(5,377)Basic and diluted loss from continuing operations per common share10 (0.02)(0.02)(0.03)(0.02)Basic and diluted loss from discontinued operations per common share10 0.00 0.00 (0.00)0.00 Basic and diluted loss per common share10 (0.02)(0.02)(0.03)(0.02)Weighted average number of common shares outstanding - basic and diluted10 280,049,434 278,556,560 279,539,697 278,552,206 Spectral Medical Inc.Condensed Interim Consolidated Statements of Changes in Shareholders’ DeficiencyIn CAD (000s)(Unaudited) NotesNumber of Shares Share Capital Contributed surplus Share-based compensation Warrants Deficit Total Shareholders’ (deficiency) equity $ $ $ $ $ $ Balance January 1, 2023 278,547,804 87,050 8,773 8,908 2,490 (109,775)(2,554)RSU released928,457 11 - (11)- - - Loss and comprehensive loss for the period - - - - - (5,377)(5,377)Share-based compensation - - - 961 - - 961 Revised (Refer note 15) Balance, June 30, 2023 278,576,261 87,061 8,773 9,858 2,490 (115,152)(6,970)Warrants issued - - - - 179 - 179 Warrants expired - - 143 - (143)- - Loss and comprehensive loss for the period - - - - - (10,285)(10,285)Share-based compensation - - - 527 - - 527 Balance December 31, 2023 278,576,261 87,061 8,916 10,385 2,526 (125,437)(16,549)Balance January 1, 2024 278,576,261 87,061 8,916 10,385 2,526 (125,437)(16,549)Warrants exercised 750,000 463 - - (90)- 373 Warrants issued - (212) - 212 - - Share Options Exercised 1,867,627 1,163 - (524)- - 639 RSU released 51,651 26 - (26)- - - Loss and comprehensive loss for the period - - - - - (8,562)(8,562)Share-based compensation - - - 1,256 - - 1,256 Balance June 30, 2024 281,245,539 88,501 8,916 11,091 2,648 (133,999)(22,843) Spectral Medical Inc.Condensed Interim Consolidated Statements of Cash FlowsIn CAD (000s)(Unaudited) Revised (Refer note 15) six months six months Notesended June 30, ended June 30, 2024 2023 Cash flow provided by (used in) Operating activities Loss for the period (8,562)(5,377)Adjustments for: Depreciation on right-of-use asset 62 47 Depreciation on property and equipment 56 53 Amortization of intangible asset 9 15 Amortization of deferred financing fee 554 49 Unrealized foreign exchange gain/loss 537 (194)Interest expense on lease liability 17 19 Accreted interest on notes payable 1,191 478 Share-based compensation expense 1,256 961 Net loss on joint venture arrangement - 163 Fair value adjustment derivative liabilities (68)(523)Changes in items of working capital: Trade and other receivables (166)314 Inventories 94 52 Prepayments and other assets (311)(866)Trade and other payables (36)(446)Contract liabilities 1,747 (333)Net cash used in operating activities (3,620)(5,588)Investing activities Purchase of property and equipment (24)(7)Net cash used in investing activities (24)(7)Financing activities Financing charges paid (722)- Interest expense paid (518)(235)Lease liability payments (76)(63)Proceeds from share options exercised 639 - Proceeds from share warrants exercised 373 - Proceed from 9% convertible notes issued 8,532 - Net cash provided by financing activities 8,228 (298)Change in cash 4,584 (5,893)Cash, beginning of period 2,952 8,414 Cash, end of period 7,536 2,521

Ten Hoedt — who is also a member of Medtronic’s Executive Committee — gave notice of his intent to retire from the world’s largest medical device company on June 1, Medtronic said in a single-sentence filing with the Securities and Exchange Commission. He was 63 years old as of April 28, according to SEC filings. In recent years, Medtronic cited a mandatory retirement age of 65 for departing executives such as former CEO Omar Ishrak, former General Counsel and Secretary Brad Lerman and former Chief Medical and Scientific Officer Dr. Rick Kuntz. Ten Hoedt’s departure comes during a time of major change at Medtronic, which includes portfolio management moves such as shuttering Medtronic’s ventilators business, layoffs and last year’s early retirement program, greater expense discipline, and increased use of automation and digitization. At the same time, the company says it has made strategic R&D investments to support future growth. MassDevice has reached out to Medtronic for more information about ten Hoedt’s retirement, including who will take over his duties. As global regions president, ten Hoedt has “full responsibility for Medtronic products and therapies” across the Americas, Europe, Middle East, Africa and Asia Pacific, the company says on its website. That includes the Hugo surgical robotics system, a program that started with Medtronic’s $43 billion acquisition of Covidien. Hugo won a CE mark in the European Union in 2021. “Robotics and artificial intelligence are the undeniable future of healthcare, with incredible potential to not only advance patient care, but increase access to these benefits,” he said in the Medtronic news release announcing Hugo’s CE mark. Medtronic’s Hugo system is not yet approved by the FDA, though the company said last month that more clinical studies are in the works to support a submission for FDA review. Medtronic named ten Hoedt as one of its top-paid executives last year, with $5 million in total compensation for fiscal 2023. He is also one of the largest individual Medtronic shareholders, with approximately 540,000 shares as of August 2023, according to an SEC filing. That filing only listed two executives with more stock at the time: Chair and CEO Geoff Martha with 795,000 shares, and former EVP and Medical Surgical President Bob White at 623,000. White — whose Medical Surgical portfolio included Hugo — also retired this year, a departure announced by Martha on the company’s third-quarter earnings call in February. Medtronic has not had an earnings call since ten Hoedt gave notice, and the company does not appear to have discussed his pending departure publicly. Rob ten Hoedt’s Medtronic career A hospital visit after a “pretty horrible accident” at the age of 18 set ten Hoedt on his career path. “Although it was a dreadful experience, I was impressed with everything that happened inside that hospital — the doctors, the nurses, the care, the way things were going,” he said in a 2014 interview filed with the SEC as the company was closing its acquisition of Covidien. “And laying in my bed looking at the ceiling, I knew that this was my destiny. I wanted to do something in healthcare.” “I’m from Europe and Europe has been living under socialized healthcare systems for as long as I’ve known,” he later continued. “But those systems are coming to a very complicated situation right now. The governments can’t afford it anymore. There’s too much demand. It’s time to transform healthcare. And I want my children and my grandchildren to have the same care that I’ve always had and I think that we as a new company can support the systems in such a way with value, economic value, with the opportunity of getting ourselves involved in the delivery of care, supporting systems, total solutions, services and solutions. I think we have the opportunity now in the new company to transform healthcare for our future and for our children.” Ten Hoedt joined Medtronic in 1991 with the title of marketing manager for Western Europe’s neurological business. “In 1994, he went on to lead the start-up of Medtronic’s Gastro-Uro business in Europe, for which he subsequently held global responsibility,” the company said at its website. “In 1999, Rob was appointed Vice President & General Manager of Vitatron, a wholly-owned subsidiary of Medtronic in The Netherlands, with responsibility for developing and marketing pacing devices. Under his leadership, Vitatron built a strong image and market position in the medical technology world.In 2006, Rob moved to Medtronic’s European headquarters in Tolochenaz, Switzerland, to lead the Western European Cardiovascular business which later expanded to Europe & Central Asia (ECA).” Ten Hoedt wrapped up his final term as board chair for MedTech Europe last year, but is still chair of the board for Medmix, chair of the supervisory board for NLC Health Ventures, and a board director for Fagron. “My personal leadership style, first of all, is all about the team and about working together,” he said in his interview during the Covidien merger. “I think you can title it as a servant leader. I don’t necessarily want to tell everybody exactly what to do but I want to facilitate a leadership team and a group of people to get the best out of themselves. And doing that in the environment of Medtronic has been a great pleasure and I’m looking forward to the next years to continue to do so.”